Tricyclic antidepressants for major depressive disorder: a comprehensive evaluation of current practice in the Netherlands

被引:10
作者
Vos, Cornelis F. [1 ,2 ]
Aarnoutse, Rob E. [3 ]
Op de Coul, Marijke J. M. [4 ]
Spijker, Jan [4 ,5 ]
Groothedde-Kuyvenhoven, Mascha M. [6 ,7 ]
Mihaescu, Raluca [8 ]
Wessels-Basten, Sonja J. W. [8 ]
Rovers, Jordy J. E. [9 ]
ter Hark, Sophie E. [1 ,2 ]
Schene, Aart H. [1 ,2 ]
Hulscher, Marlies E. J. L. [10 ]
Janzing, Joost G. E. [1 ,2 ]
机构
[1] Radboud Univ Nijmegen, Dept Psychiat, Med Ctr, Reinier Postlaan 10, NL-6500 HB Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Nijmegen, Netherlands
[3] Radboud Univ Nijmegen, Med Ctr, Dept Pharm Radboud Inst Hlth Sci, Nijmegen, Netherlands
[4] Radboud Univ Nijmegen, Nijmegen, Netherlands
[5] Pro Persona, Nijmegen, Netherlands
[6] Deventer Hosp, Deventer, Netherlands
[7] Dimence Grp, Deventer, Netherlands
[8] Catharina Hosp, Eindhoven, Netherlands
[9] Vincent van Gogh Inst Psychiat, Venray, Netherlands
[10] Radboud Univ Nijmegen, Sci Ctr Qual Hlthcare, Med Ctr, Nijmegen, Netherlands
关键词
Antidepressant agents; Clinical practice guidelines; Qualitative approach; Major depressive disorder; Tricyclic antidepressants; GUIDELINES;
D O I
10.1186/s12888-021-03490-x
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background Traditionally tricyclic antidepressants (TCAs) have an important place in treatment of major depressive disorder (MDD). Today, often other antidepressant medications are considered as first step in the pharmacological treatment of MDD, mainly because they are associated with less adverse effects, whereby the position of TCAs appears unclear. In this study we aimed to examine the current practice of TCAs in treatment of unipolar MDD. Methods A mixed methods approach was applied. First, a selection of leading international and national guidelines was reviewed. Second, actual TCA prescription was examined by analyzing health records of 75 MDD patients treated with the TCAs nortriptyline, clomipramine or imipramine in different centers in the Netherlands. Third, promotors and barriers influencing the choice for TCAs and dosing strategies were explored using semi-structured interviews with 24 Dutch psychiatrists. Results Clinical practice guidelines were sometimes indirective and inconsistent with each other. Health records revealed that most patients (71%) attained therapeutic plasma concentrations within two months of TCA use. Patients who achieved therapeutic plasma concentrations reached them on average after 19.6 days (SD 10.9). Both health records and interviews indicated that therapeutic nortriptyline concentrations were attained faster compared to other TCAs. Various factors were identified influencing the choice for TCAs and dosing by psychiatrists. Conclusions Guideline recommendations and clinical practice regarding TCA prescription for MDD vary. To increase consistency in clinical practice we recommend development of an up-to-date guideline integrating selection and dosing of TCAs, including the roles of therapeutic drug monitoring and pharmacogenetics. Such a guideline is currently lacking and would contribute to optimal TCA treatment, whereby efficacy and tolerability may be increased.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review
    Bruno, Antonio
    Morabito, Paolo
    Spina, Edoardo
    Muscatello, Maria Rosaria
    CURRENT NEUROPHARMACOLOGY, 2016, 14 (02) : 191 - 199
  • [32] Prioritization and comprehensive analysis of genes related to major depressive disorder
    Liu, Yi
    Fan, Pengfei
    Zhang, Shiyuan
    Wang, Yidan
    Liu, Dan
    MOLECULAR GENETICS & GENOMIC MEDICINE, 2019, 7 (06):
  • [33] MicroRNAs as Critical Biomarkers of Major Depressive Disorder: A Comprehensive Perspective
    Ortega, Miguel A.
    Angel Alvarez-Mon, Miguel
    Garcia-Montero, Cielo
    Fraile-Martinez, Oscar
    Lahera, Guillermo
    Monserrat, Jorge
    Munoz-Merida, Luis
    Mora, Fernando
    Rodriguez-Jimenez, Roberto
    Fernandez-Rojo, Sonia
    Quintero, Javier
    Alvarez-Mon, Melchor
    BIOMEDICINES, 2021, 9 (11)
  • [34] The relationship between fibromyalgia and major depressive disorder: a comprehensive review
    Pae, Chi-Un
    Luyten, Patrick
    Marks, David M.
    Han, Changsu
    Park, Sung-Hwan
    Patkar, Ashwin A.
    Masand, Prakash S.
    Van Houdenhove, Boudewijn
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (08) : 2359 - 2371
  • [35] Risk-to-befit ratios of consecutive antidepressants for heavy menstrual bleeding in young women with bipolar disorder or major depressive disorder
    Zhuo, Chuanjun
    Chen, Guangdong
    Lin, Chongguang
    Ping, Jing
    Zhu, Jingjing
    Wang, Lina
    Jin, Shili
    Liu, Chuanxin
    Zhang, Qiuyu
    Yang, Lei
    Li, Qianchen
    Zhou, Chunhua
    Cheng, Langlang
    Tian, Hongjun
    Song, Xueqin
    FRONTIERS IN PSYCHIATRY, 2022, 13
  • [36] What combinations of agomelatine with other antidepressants could be successful during the treatment of major depressive disorder or anxiety disorders in clinical practice?
    Potmesil, Petr
    THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2019, 9
  • [37] Retinal markers of therapeutic responses in major depressive disorder: Effects of antidepressants on retinal function
    Moulard, Marie
    Cosker, Eve
    Angioi-Duprez, Karine
    Laprevote, Vincent
    Schwan, Raymund
    Schwitzer, Thomas
    JOURNAL OF PSYCHIATRIC RESEARCH, 2022, 154 : 71 - 79
  • [38] Efficacy and tolerability of antidepressants for sub-threshold depression and for mild major depressive disorder
    Cameron, Isobel M.
    Reid, Ian C.
    MacGillivray, Steve A.
    JOURNAL OF AFFECTIVE DISORDERS, 2014, 166 : 48 - 58
  • [39] A comprehensive review and meta-analysis of neurological side effects related to second-generation antidepressants in individuals with major depressive disorder
    Zhou, Qi
    Li, Xinming
    Yang, Dejiang
    Xiong, Chongyu
    Xiong, Zhenrong
    BEHAVIOURAL BRAIN RESEARCH, 2023, 447
  • [40] Learning from negative feedback in patients with major depressive disorder is attenuated by SSRI antidepressants
    Herzallah, Mohammad M.
    Moustafa, Ahmed A.
    Natsheh, Joman
    Abdellatif, Salam M.
    Taha, Mohamad B.
    Tayem, Yasin L.
    Sehwail, Mahmud A.
    Amleh, Ivona
    Petrides, Georgios
    Myers, Catherine E.
    Gluck, Mark A.
    FRONTIERS IN INTEGRATIVE NEUROSCIENCE, 2013, 7